Valuation : Lupin Limited

Market Cap 994B 10.41B 8.97B 8.41B 7.67B 14.46B 14.5B 99.74B 38.92B 502B 39.07B 38.22B 1,665B P/E 2027 *
22.6x
P/E 2028 * 21.3x
Enterprise Value 951B 9.95B 8.57B 8.04B 7.34B 13.82B 13.87B 95.36B 37.2B 480B 37.35B 36.54B 1,591B EV / Sales 2027 *
3.14x
EV / Sales 2028 * 2.84x
Free-Float
52.98%
Yield 2027 *
0.58%
Yield 2028 * 0.59%
1 day+0.48%
1 week-0.82%
Current month-9.90%
1 month-11.22%
3 months-4.29%
6 months-5.49%
Current year+2.98%
1 week 2,145.35
Extreme 2145.35
2,237
1 month 2,145.35
Extreme 2145.35
2,447.95
Current year 2,072.95
Extreme 2072.95
2,530
1 year 1,881.8
Extreme 1881.8
2,530
3 years 1,088.3
Extreme 1088.3
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 01/09/2013
Director of Finance/CFO 61 13/08/2007
Compliance Officer - 01/09/2024
Director TitleAgeSince
Director/Board Member 52 08/10/2008
Director/Board Member 58 01/01/1997
Chairman 82 11/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%-0.82%+14.89%+98.26% 10.41B
-0.13%-6.44%+60.34%+112.06% 1,047B
+0.85%-0.81%+51.29%+63.13% 646B
-1.03%-3.58%+21.43%+73.10% 451B
-1.46%-4.50%+37.80%+37.41% 355B
-0.72%-2.89%+22.32%+36.62% 291B
-1.19%-2.21%+1.53%+10.79% 252B
-1.05%-1.57%+50.30%+66.55% 234B
+0.08%-1.78%-17.64%-54.36% 203B
-2.14%-0.30%+28.95%+86.27% 181B
Average -0.63%-2.49%+27.12%+52.98% 366.97B
Weighted average by Cap. -0.46%-3.45%+38.10%+65.10%

Financials

2027 *2028 *
Net sales 303B 3.17B 2.73B 2.56B 2.34B 4.4B 4.42B 30.39B 11.86B 153B 11.9B 11.64B 507B 322B 3.37B 2.9B 2.72B 2.48B 4.68B 4.7B 32.29B 12.6B 163B 12.65B 12.37B 539B
Net income 44.09B 461M 398M 373M 340M 641M 643M 4.42B 1.73B 22.26B 1.73B 1.69B 73.8B 46.71B 489M 421M 395M 360M 679M 681M 4.68B 1.83B 23.58B 1.83B 1.79B 78.18B
Net Debt -43.72B -457M -394M -370M -337M -636M -638M -4.38B -1.71B -22.07B -1.72B -1.68B -73.17B -78.59B -822M -709M -664M -606M -1.14B -1.15B -7.88B -3.08B -39.67B -3.09B -3.02B -132B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
28/08/26 ₹2,175.00 +0.48% 15,828
27/08/26 ₹2,164.60 -1.21% 48,999
26/08/26 ₹2,191.20 +0.74% 30,394
25/08/26 ₹2,175.00 -0.68% 190,477
24/08/26 ₹2,190.00 -0.14% 12,257
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
2,175.00INR
Average target price
2,496.28INR
Spread / Average Target
+14.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock